SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its plans to create an integrated digital health and rewards platform which will use a utility cryptocurrency called QB. The QB coins are being developed by a third party, and are scheduled to be launched sometime in January 2026 for use in EUDA’s digital health and wel ...

Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds.Kymera Therapeutics Inc. (KYMR) surged in extended trading, climbing to $73.00, a 9.58% rise from the close. Shares had ended the regular session at $66.62, up modestly by 0.59%. The company is preparing to announce results from the BroADen Phase 1b clinical trial of KT-621, its oral STAT6 degrader for moderate to severe at ...

Core Viewpoint - EUDA Health Holdings Limited has entered into a securities purchase agreement with Streeterville Capital for a convertible warrant, aiming to strengthen its capital position and support growth strategies in the non-invasive healthcare market in Asia [1][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider focusing on Singapore, Malaysia, and China, with a mission to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care [5]. - The company targets the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [5]. Financial Details - The securities purchase agreement involves the sale of a convertible warrant for an aggregate purchase price of US$100,000, which is exercisable for up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share [1][3]. - The warrant can be exercised for cash within a 90-day period, with conditions allowing the company to require Streeterville Capital to exercise the warrant under specific trading volume and price conditions [3]. Strategic Intent - The CEO of EUDA emphasized that the warrant financing provides flexibility to invest in high-return initiatives, including new centers, partnerships, and technology, to expand the company's footprint in Asia's non-invasive healthcare market [4].

Core Insights - EUDA Health Holdings Limited is expanding into the Indian market through a partnership with SafeRock India, aiming to leverage the growing wellness and preventive healthcare industry in India [1][3]. Market Opportunity and Growth Potential - India is becoming a significant player in the global wellness and preventive healthcare sector, driven by a growing middle class, urbanization, and a focus on long-term health [2]. - Consumers are increasingly seeking healthier lifestyles and science-based solutions that align with modern living [2]. Partnering for Rapid Strategic Market Entry - The partnership with SafeRock India allows CK Health Plus to enter one of the largest and fastest-growing wellness markets, with plans to expand into major cities like Mumbai, Bangalore, and Karnataka [3]. Building a Sustainable Wellness Ecosystem - The collaboration combines CK Health Plus' Bioenergy Capsule Therapies and EUDA Helixé supplements with SafeRock India's operational presence, aiming to create a sustainable wellness ecosystem [4]. Executive Commentary - The CEO of CK Health Plus emphasized that the partnership with SafeRock India is crucial for delivering scientifically-backed wellness solutions across India, aligning with the company's mission to enhance preventive healthcare accessibility [5]. About EUDA Health Holdings Limited - EUDA Health Holdings Limited focuses on non-invasive healthcare in Asia, particularly in Singapore, Malaysia, and China, targeting the growing longevity sector and addressing the healthcare needs of over 1.8 billion people in the region [6].

Core Insights - EUDA Health Holdings Limited has received a Direct Selling License for its subsidiary CK Health Plus, enabling compliant direct selling and multi-level marketing operations in Malaysia [1][2]. License Approval and Compliance - The Direct Selling License allows CK Health Plus to recruit members, distribute wellness products, and operate its network marketing model in accordance with Malaysia's Direct Selling Act 1993 [2]. Expansion and Strategic Rollout - With the License, the company plans to accelerate the rollout of Bioenergy Capsule Centers and expand the distribution of EUDA Helixé supplements, enhancing synergies within its agent network in Malaysia and Singapore [3]. Building an Ethical Preventative Healthcare Network - CK Health Plus focuses on training agents in product knowledge to ensure ethical customer engagement, aiming to create a sustainable model that aligns financial success with social impact [4]. Executive Commentary - CEO Alex Lai emphasized that the License provides the operational framework to scale expansion, empowering individuals to take control of their health and create business opportunities in the non-invasive wellness sector [5]. About EUDA Health Holdings Limited - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, targeting the growing longevity sector and addressing the healthcare needs of over 1.8 billion people in the region, particularly as more than 30% of the population ages rapidly [6].

Financial Performance - Total revenues for the six months ended June 30, 2025, increased to $3,057,323, representing a 60% growth compared to $1,908,048 for the same period in 2024[5] - Gross profit for the same period was $835,314, up from $442,072, indicating a significant improvement in profitability[5] - The net loss attributable to Euda Health Holdings Limited for the six months ended June 30, 2025, was $1,204,001, a reduction from a net loss of $16,827,829 in the prior year[5] - The company reported a gross profit margin of approximately 27% for the six months ended June 30, 2025, compared to 23% in the same period of 2024[5] - For the six months ended June 30, 2025, the net loss from continuing operations was $1,201,696, a significant improvement compared to a net loss of $16,748,274 for the same period in 2024, representing an 92.83% reduction[9] - The total loss before income taxes for the six months ended June 30, 2025, was $1,205,970, a significant decrease from $16,749,253 for the same period in 2024[159] - The provision for income taxes for the six months ended June 30, 2025, was a benefit of $4,274, compared to a benefit of $979 for the same period in 2024[159] Assets and Liabilities - Total current assets increased to $1,306,436 as of June 30, 2025, compared to $762,876 as of December 31, 2024, reflecting a 71% increase[2] - Total liabilities rose to $5,848,771 as of June 30, 2025, compared to $4,269,878 at the end of 2024, marking a 37% increase[2] - The accumulated deficit increased to $(51,304,427) as of June 30, 2025, from $(50,100,426) at the end of 2024[3] - As of June 30, 2025, the company's working capital deficit was approximately $4.4 million, with cash on hand of approximately $0.2 million[17] - The company had total accounts receivable of $426,688 as of June 30, 2025, up from $146,174 as of December 31, 2024[106] - The Company’s total intangible assets, net, were valued at $260,370 as of June 30, 2025, compared to $337,295 as of December 31, 2024[111] Cash Flow and Financing - The net cash used in operating activities from continuing operations was $1,215,423, slightly higher than $1,120,810 in the prior year, indicating a 8.45% increase in cash outflow[9] - The company reported cash paid for income tax of $28,943, compared to $11,533 in the previous year, reflecting a 150.56% increase[10] - The total cash at the end of the period was $176,584, down from $390,578 at the end of the same period in 2024, marking a 54.8% decrease[10] - The company reported a net cash provided by financing activities from continuing operations of $1,117,757, compared to $1,299,775 in the previous year, indicating a 14.0% decrease[10] - The company has an ongoing need to raise additional cash from outside sources to fund its operations and expansion plans[17] Business Operations and Strategy - The company has expanded its operations to provide non-invasive healthcare products and services in Asia, focusing on Singapore, Malaysia, and China[12] - The company streamlined its medical services practice, which has been accounted for as a discontinued operation, significantly impacting its financial results[12] - The company reorganized its business into two reportable segments: property management services and holistic wellness consumer products and services[29] - The company is in the process of transitioning its business to other medical service fields, which has been accounted for as a discontinued operation due to its significant impact on operations and financial results[96] Shareholder and Equity Information - The weighted average number of ordinary shares increased to 37,156,364 for the six months ended June 30, 2025, from 28,370,557 in the prior year[6] - The basic and diluted loss per share for continuing operations was $(0.03) for the six months ended June 30, 2025, compared to $(0.59) for the same period in 2024[76] - The company issued 940,000 ordinary shares at $1.00 per share for a total of $940,000 in a private placement between May 16 and May 22, 2023, later canceling 200,000 shares due to non-payment[135] - The company has the potential to issue up to 4,000,000 Earnout Shares based on achieving specific share price and financial performance metrics over the next two years[151][152] Impairment and Losses - The company recognized an impairment loss on goodwill of $14,755,560 in the previous year, which was not present in the current period[9] - Nil impairment of intangible assets was recorded for the six months ended June 30, 2025, compared to $14,755,560 for the same period in 2024[42] - The company reported impairment losses on long-lived assets of $14,755,560 for the six months ended June 30, 2024, while no impairment losses were recognized for the same period in 2025[43] Legal and Regulatory Matters - The company is not currently involved in any material legal proceedings as of June 30, 2025[179] - The company filed an application to set aside a statutory demand for $138,202.66, which was found to have a substantial dispute and was ordered to be set aside[178] Segment Performance - The property management services segment generated $2,089,041 in revenue, while the holistic wellness consumer products and services segment contributed $893,785[183] - The company reported a segment loss of $(207,539) for the six months ended June 30, 2025, compared to a loss of $(729,989) for the same period in 2024, indicating an improvement in operational performance[183][185]

Core Insights - EUDA Health Holdings Limited has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore [1][2] - GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that can reprogram human blood cells into clinical-grade stem cells, which have applications in drug discovery, disease modeling, and regenerative medicine [2][3] - The collaboration aims to establish a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China, to supply iPSC solutions to hospitals and research centers [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [5] - The company aims to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [5] Strategic Initiatives - The collaboration with GO POSB will enable EUDA to supply B2B iPSC solutions to the healthcare ecosystem, including hospitals and biotech developers [4] - Future opportunities include off-the-shelf iPSC-derived products tailored for Asia's wellness and aesthetics markets, complementing EUDA's existing portfolio of stem cell treatments [4]

Core Insights - EUDA Health Holdings Limited has secured distribution rights for T-cell immunotherapies in Malaysia from Shenzhen Inno Immune Co. Ltd, marking a significant expansion into advanced cell therapy [1][2] - The T-cell immunotherapy package will be priced at USD 8,000 per treatment, significantly lower than traditional costs in the region, making it more accessible [4] - This partnership is part of EUDA's strategy to diversify its healthcare portfolio and focus on regenerative and longevity medicine, addressing the healthcare needs of an aging population in Asia [5][6] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to transform healthcare from reactive treatment to proactive, longevity-focused care [6] - The company aims to address the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [6] - EUDA also operates a property management business in Singapore, further diversifying its operations [6] Strategic Partnerships - The agreement with Shenzhen Inno is facilitated by Guangdong Key Lock Health Management Co., Ltd, which has a long-term strategic partnership with both EUDA and Shenzhen Inno [3] - This partnership is expected to enhance EUDA's offerings in immune-enhancing therapies, leveraging Shenzhen Inno's scientific and institutional backing [5][8]

Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [6] - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [6] Acquisition Announcement - EUDA has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd, a Singapore-based biotech company [1][2] - The exclusivity period for Chemokine is set for at least 120 days, during which it cannot engage in discussions with other entities regarding similar transactions [2] Chemokine Overview - Chemokine specializes in molecular supplements and gene modulating formulations, including a next-generation immune health supplement for which EUDA has obtained exclusive worldwide distribution rights [3] - The company was founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [4] Product Differentiation - Euda Helixé, the product marketed by EUDA, is designed to support energy, immune resilience, and cellular health, utilizing a unique formulation that includes molecular deer placenta, marine collagen, and bioactive antioxidants [5] - The product employs a gene activation model to modulate gene expression, activating beneficial genes while silencing harmful ones [5]

Core Viewpoint - EUDA Health Holdings Limited has secured exclusive worldwide distribution rights for a next-generation immune health supplement, enhancing its wellness product portfolio and positioning itself in the molecular precision wellness market [1][7]. Group 1: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [1][8]. - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [8][10]. Group 2: Product Details - The newly acquired supplement, branded as Euda Helixé, is designed to modulate gene expression, enhancing metabolism, boosting vitality, and supporting longevity through advanced epigenetic technology [2][3]. - The supplement combines premium-grade ingredients and utilizes a capsule delivery system that ensures active ingredients survive stomach acid for optimal absorption [4][9]. Group 3: Market Strategy - EUDA plans to initially market and sell the supplement in Singapore, Malaysia, and China, with future expansion into other markets [2]. - The company anticipates generating sales of approximately 500,000 bottles over the next 12 months, leveraging its strong regional ecosystem and distribution capabilities [7]. Group 4: Scientific Background - The supplement is developed by Chemokine Pte. Ltd., founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [6]. - The formulation builds on prior scientific advancements and proven platforms to deliver molecular-level wellness support [4].